Ventum Cap Mkts Weighs in on Cresco Labs FY2026 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF) – Ventum Cap Mkts issued their FY2026 earnings estimates for Cresco Labs in a research note issued on Monday, November 11th. Ventum Cap Mkts analyst A. Semple anticipates that the company will post earnings per share of ($0.06) for the year. Ventum Cap Mkts has a “Strong-Buy” rating on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.19) per share.

CRLBF has been the subject of a number of other research reports. Needham & Company LLC reiterated a “hold” rating on shares of Cresco Labs in a report on Monday, August 12th. Roth Capital raised Cresco Labs to a “strong-buy” rating in a report on Sunday. Two analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Cresco Labs currently has a consensus rating of “Buy” and an average target price of $2.50.

Cresco Labs Stock Up 14.3 %

CRLBF opened at $1.44 on Wednesday. The company has a debt-to-equity ratio of 1.76, a current ratio of 2.00 and a quick ratio of 1.30. Cresco Labs has a 12 month low of $1.02 and a 12 month high of $2.65. The stock has a market capitalization of $702.92 million, a P/E ratio of -7.10 and a beta of 1.88. The business has a 50 day simple moving average of $1.58 and a 200-day simple moving average of $1.71.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.